CA3176559A1 - 25-hydroxyvitamin d for the treatment of sars-cov-2 infection - Google Patents

25-hydroxyvitamin d for the treatment of sars-cov-2 infection

Info

Publication number
CA3176559A1
CA3176559A1 CA3176559A CA3176559A CA3176559A1 CA 3176559 A1 CA3176559 A1 CA 3176559A1 CA 3176559 A CA3176559 A CA 3176559A CA 3176559 A CA3176559 A CA 3176559A CA 3176559 A1 CA3176559 A1 CA 3176559A1
Authority
CA
Canada
Prior art keywords
hydroxyvitamin
day
subject
level
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3176559A
Other languages
English (en)
French (fr)
Inventor
Charles W. Bishop
Stephen A. Strugnell
Akhtar Ashfaq
Reem Elamein ELSIDDIG
Colm Nulty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eirgen Pharma Ltd
Original Assignee
Eirgen Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eirgen Pharma Ltd filed Critical Eirgen Pharma Ltd
Publication of CA3176559A1 publication Critical patent/CA3176559A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3176559A 2020-04-06 2021-04-06 25-hydroxyvitamin d for the treatment of sars-cov-2 infection Pending CA3176559A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063006034P 2020-04-06 2020-04-06
US63/006,034 2020-04-06
US202063006563P 2020-04-07 2020-04-07
US63/006,563 2020-04-07
US202063009155P 2020-04-13 2020-04-13
US63/009,155 2020-04-13
US202063012781P 2020-04-20 2020-04-20
US63/012,781 2020-04-20
US202063032714P 2020-05-31 2020-05-31
US63/032,714 2020-05-31
PCT/IB2021/000220 WO2021205225A1 (en) 2020-04-06 2021-04-06 25-hydroxyvitamin d for the treatment of sars-cov-2 infection

Publications (1)

Publication Number Publication Date
CA3176559A1 true CA3176559A1 (en) 2021-10-14

Family

ID=75904967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3176559A Pending CA3176559A1 (en) 2020-04-06 2021-04-06 25-hydroxyvitamin d for the treatment of sars-cov-2 infection

Country Status (8)

Country Link
US (2) US20210308151A1 (enExample)
EP (1) EP4132477A1 (enExample)
JP (1) JP2023520591A (enExample)
KR (1) KR20220164539A (enExample)
CN (1) CN116033940A (enExample)
CA (1) CA3176559A1 (enExample)
TW (1) TW202203936A (enExample)
WO (1) WO2021205225A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2862462B2 (es) * 2020-04-06 2023-04-27 Servicio Andaluz De Salud Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda
CN120694962A (zh) * 2020-05-31 2025-09-26 艾尔金制药有限公司 硬胶囊剂型和其用途
CN116785295A (zh) * 2023-06-29 2023-09-22 吉林大学 雷特格韦在防治新型冠状病毒感染药物中的应用
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264223A (en) 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
FR2757173A1 (fr) 1996-12-17 1998-06-19 Warner Lambert Co Compositions polymeres d'origine non-animale pour la formation de films
KR100379674B1 (ko) 2000-03-06 2003-04-10 주식회사 서흥캅셀 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법
ES2593047T3 (es) * 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
US20080031957A1 (en) 2006-05-15 2008-02-07 Deluca Hector F Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
KR20190028822A (ko) * 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
JP2017523220A (ja) * 2014-08-07 2017-08-17 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法
JP7032322B2 (ja) * 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
JP7603000B2 (ja) 2018-08-31 2024-12-19 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ小児用剤形、製造方法および使用方法

Also Published As

Publication number Publication date
JP2023520591A (ja) 2023-05-17
CN116033940A (zh) 2023-04-28
KR20220164539A (ko) 2022-12-13
EP4132477A1 (en) 2023-02-15
WO2021205225A1 (en) 2021-10-14
US20210308151A1 (en) 2021-10-07
WO2021205225A8 (en) 2023-01-05
US20250144119A1 (en) 2025-05-08
TW202203936A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
US20250144119A1 (en) Activating endogenous antimicrobials to treat sars-cov-2 infection
KR20160066554A (ko) 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
US20070149465A1 (en) Compositions and methods for prevention and treatment of cachexia
US20240100029A1 (en) Treatment of migraine
Davidson et al. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index≥ 27 kg/m2
US20190358240A1 (en) Hiv treatment formulation of atazanavir and cobicistat
US20230330110A1 (en) Hard capsule dosage form and uses thereof
CN116234542A (zh) 代谢物的免疫效应
Bassuk et al. Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence
CN115397431A (zh) 用于治疗涉及全身过度炎症反应的病症的eclitasertib
WO2021195119A1 (en) Methods of reducing the risk of, severity of, and treating coronavirus infections
WO2021199006A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
CN119421712A (zh) 用于多发性硬化和重症肌无力的治疗性酪氨酸激酶抑制剂
Safe et al. Praia Marins, AF, Rebelo Rabelo, A. L., Costa, AA, et al.(2020). Safety and efficacy of n-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB study)
Wang et al. Celiac disease and drug absorption: implications for cardiovascular therapeutics
JP2017533239A (ja) 不安定または吸収不良薬物の経口投与
Zhang et al. Free fatty acid receptor 4 in cardiac myocytes ameliorates ischemic cardiomyopathy
WO2021132302A1 (ja) 透析移行又は腎死の抑制のための薬剤
US20250221947A1 (en) Methods for treating a coronavirus infection using valproic acid and docosahexaenoic acid
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
US20240009154A1 (en) Methods and compositions for treating cytokine release syndrome
US20210204872A1 (en) Use of heart rate variability (hrv) in infectious disease prognosis and treatment
WO2026047543A1 (en) Isolithocholic acid for use in the prevention or treatment of inflammatory diseases of the respiratory system
Traynor New drug and biological product approvals, 2012.
JP2011105653A (ja) 花粉症抑制剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250407

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250806

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250811

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250915

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250915